<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447262</url>
  </required_header>
  <id_info>
    <org_study_id>VX17-659-105</org_study_id>
    <secondary_id>2017-004134-29</secondary_id>
    <nct_id>NCT03447262</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy</brief_title>
  <official_title>A Phase 3, Open-label Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the long-term safety and tolerability of VX-659 in triple
      combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis
      (CF), including but not limited to those who are heterozygous for the F508del mutation
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2018</start_date>
  <completion_date type="Anticipated">April 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of long-term treatment with VX-659 in TC with TEZ and IVA based on adverse events (AEs)</measure>
    <time_frame>from baseline through safety follow-up (up to 100 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in ppFEV1</measure>
    <time_frame>from baseline through last dose of study drug (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in sweat chloride (SwCl)</measure>
    <time_frame>from baseline through last dose of study drug (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pulmonary exacerbations (PEx)</measure>
    <time_frame>from baseline through last dose of study drug (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first PEx</measure>
    <time_frame>from baseline through last dose of study drug (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body mass index (BMI)</measure>
    <time_frame>from baseline through last dose of study drug (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in BMI z-score</measure>
    <time_frame>from baseline through last dose of study drug (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body weight</measure>
    <time_frame>from baseline through last dose of study drug (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from baseline in CFQ-R respiratory domain score</measure>
    <time_frame>from baseline through last dose of study drug (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Open-label triple combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 240 mg VX-659 / 100 mg TEZ / 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.
Parent studies are Phase 3 Vertex studies investigating VX-659 in combination with TEZ and IVA. This includes, but is not limited to, Study VX17-659-102.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-659</intervention_name>
    <description>Fixed-dose combination (FDC) tablets (VX-659/TEZ/IVA)</description>
    <arm_group_label>Open-label triple combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEZ</intervention_name>
    <description>FDC tablets (VX-659/TEZ/IVA)</description>
    <arm_group_label>Open-label triple combination</arm_group_label>
    <other_name>tezacaftor; VX-661</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>FDC tablets (VX-659/TEZ/IVA)</description>
    <arm_group_label>Open-label triple combination</arm_group_label>
    <other_name>ivacaftor; VX-770</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>IVA tablet</description>
    <arm_group_label>Open-label triple combination</arm_group_label>
    <other_name>ivacaftor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completed study drug treatment in a parent study; or had study drug interruption(s) in
             a parent study but completed study visits up to the last scheduled visit of the
             Treatment Period in the parent study.

        Exclusion Criteria:

          -  History of drug intolerance in a parent study that would pose an additional risk to
             the subject in the opinion of the investigator.

          -  Current participation in an investigational drug trial (other than a parent study)

        Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

